Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multi-site, Exploratory Study
Sponsor: Chipscreen Biosciences, Ltd.
A PHASE1/PHASE2 clinical study on Ovarian Cancer, this trial is completed. The trial is conducted by Chipscreen Biosciences, Ltd. and has accumulated 9 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Feb 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chipscreen Biosciences, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .